Ken Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ken Suzuki has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Yasunori Shintani
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
14 shared publications Yuki Ichihara
William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK
13 shared publicationsKenta Yashiro
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
11 shared publicationsLaura Fields
William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK
11 shared publicationsMasahiro Kaneko
Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England
9 shared publicationsTomoya Ito
William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK
9 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-3
Author Correction: IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice
- 1 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-3
Open AccessAuthor Correction: IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice
- Open Access
- 25 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-6
Author Correction: Fibrin Glue-aided, Instant Epicardial Placement Enhances the Efficacy of Mesenchymal Stromal Cell-Based Therapy for Heart Failure
- 25 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-6
Open AccessAuthor Correction: Fibrin Glue-aided, Instant Epicardial Placement Enhances the Efficacy of Mesenchymal Stromal Cell-Based Therapy for Heart Failure
- Open Access
TGF-β Signalling Drives Chemotaxis of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Response to MI Stimulus
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold significant promise for cardiac regeneration therapies. However, the efficacy of such treatments depends on the ability of transplanted cells to migrate and integrate into the damaged myocardium, a process that remains poorly understood. In this study, we investigated the migratory behaviour of hiPSC-CMs using homogenised rat MI tissue to simulate myocardial infarction (MI) in vitro . Transwell migration assays demonstrated a concentration-dependent chemotactic response, with hiPSC-CM migration increasing up to threefold toward MI tissue homogenate. Wound healing assays further confirmed enhanced migration under MI-mimetic conditions. Bulk RNA sequencing revealed activation of the TGF-β signalling pathway as a key regulator of this response. Inhibition of TGF-β signalling, both pharmacologically and through antibody neutralisation, significantly reduced hiPSC-CM migration. These findings uncover a previously underappreciated chemotactic capability of hiPSC-CMs and identify TGF-β signalling as a central mediator, offering new mechanistic insights and potential therapeutic targets to improve the integration and efficacy of hiPSC-CM-based cardiac regeneration strategies.
Open AccessTGF-β Signalling Drives Chemotaxis of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Response to MI Stimulus
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold significant promise for cardiac regeneration therapies. However, the efficacy of such treatments depends on the ability of transplanted cells to migrate and integrate into the damaged myocardium, a process that remains poorly understood. In this study, we investigated the migratory behaviour of hiPSC-CMs using homogenised rat MI tissue to simulate myocardial infarction (MI) in vitro . Transwell migration assays demonstrated a concentration-dependent chemotactic response, with hiPSC-CM migration increasing up to threefold toward MI tissue homogenate. Wound healing assays further confirmed enhanced migration under MI-mimetic conditions. Bulk RNA sequencing revealed activation of the TGF-β signalling pathway as a key regulator of this response. Inhibition of TGF-β signalling, both pharmacologically and through antibody neutralisation, significantly reduced hiPSC-CM migration. These findings uncover a previously underappreciated chemotactic capability of hiPSC-CMs and identify TGF-β signalling as a central mediator, offering new mechanistic insights and potential therapeutic targets to improve the integration and efficacy of hiPSC-CM-based cardiac regeneration strategies.
- Open Access
- 13 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122611
Corrigendum to “Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure” [Biomaterials 154 (2018) 12–23]
- 13 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122611
Open AccessCorrigendum to “Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure” [Biomaterials 154 (2018) 12–23]
- Open Access
- 1 March 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (4) , 2145
Author Correction: Toll‐like receptor 9 protects non‐immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2
- 1 March 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (4) , 2145
Open AccessAuthor Correction: Toll‐like receptor 9 protects non‐immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2
- Open Access
- 9 February 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122500
Corrigendum to “Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure” [Biomaterials 154 (2018) 12–23]
- 9 February 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122500
Open AccessCorrigendum to “Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure” [Biomaterials 154 (2018) 12–23]
- Open Access
- 9 February 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122499
Corrigendum to “On-site fabrication of bi-layered adhesive mesenchymal stromal cell dressings for the treatment of heart failure” [Biomaterials 209 (2019) 41–53]
- 9 February 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122499
Open AccessCorrigendum to “On-site fabrication of bi-layered adhesive mesenchymal stromal cell dressings for the treatment of heart failure” [Biomaterials 209 (2019) 41–53]
- Open Access
- 22 December 2023
- Published by Elsevier in Molecular Therapy
- Vol. 32 (2) , 562
Epicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data
- 22 December 2023
- Published by Elsevier in Molecular Therapy
- Vol. 32 (2) , 562
Open AccessEpicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data
- Open Access
- 1 August 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (8) , 2554-2570
Epicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data
- 1 August 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (8) , 2554-2570
Open AccessEpicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data